Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Friday

Child & Adolescent Psychiatry Gilbert, AZ Medical Doctor

NPI 1134352933 CMS profile 50985

2730 S Val Vista Dr, Suite 137, Gilbert, AZ 85295

Open in the dashboard

General payments

$18,283

1,125 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Friday of Gilbert, AZ is reported in the CMS Open Payments database as having received $18,283 across 1,125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,382 218
2024 General $3,351 192
2023 General $2,886 167
2022 General $2,806 161
2021 General $2,345 158
2020 General $1,757 108
2019 General $1,757 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Friday
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Jason Friday were reported at $3,382. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Jason Friday Child & Adolescent Psychiatry median Middle half National median
2019 $1,757 $129 $42–$419 $163
2020 $1,757 $81 $28–$226 $114
2021 $2,345 $115 $31–$326 $132
2022 $2,806 $124 $40–$382 $149
2023 $2,886 $130 $45–$420 $160
2024 $3,351 $141 $42–$490 $164
2025 $3,382 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,206 152 payments
  2. Otsuka America Pharmaceutical, Inc. $1,597 99 payments
  3. Tris Pharma Inc $1,450 106 payments
  4. ITI, Inc. $1,216 65 payments
  5. Corium, Inc. $1,202 69 payments
  6. Lundbeck LLC $1,181 73 payments
  7. Sunovion Pharmaceuticals Inc. $1,053 57 payments
  8. Axsome Therapeutics, Inc. $941 50 payments
  9. Ironshore Pharmaceuticals Inc. $888 51 payments
  10. Vanda Pharmaceuticals Inc. $751 40 payments
  11. Other $5,797 363 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,172 1,122 payments
  2. Education $111 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,704 111 payments
  2. Azstarys $1,202 69 payments
  3. LATUDA $1,053 57 payments
  4. VRAYLAR Neuroscience $1,048 83 payments
  5. CAPLYTA $1,033 54 payments
  6. REXULTI Psychiatry $887 54 payments
  7. Auvelity $857 47 payments
  8. Dyanavel XR $833 63 payments
  9. REXULTI Psychiatry $765 58 payments
  10. FANAPT $735 39 payments
  11. Other $11,099 647 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

360

Median for Neuropsychiatry: 88

Drug cost

$191,523

Median for Neuropsychiatry: $2,689

Branded share of claims

38.9%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 12 $101,942
Vraylar Cariprazine Hcl Brand 33 $50,158
Abilify Maintena Aripiprazole Brand 12 $26,139
Trintellix Vortioxetine Hydrobromide Brand 11 $8,298
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 21 $729
Methylphenidate Hcl Generic 13 $719
Bupropion Xl Bupropion Hcl Brand 27 $664
Mirtazapine Generic 14 $411
Lamotrigine Generic 20 $385
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 11 $380

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$684 33 —
REXULTI
$348 — —
CAPLYTA
$320 — —
Azstarys
$271 — —
JORNAY PM
$267 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record